StoneX Group’s Cellyan Biotechnology HKPD Stock Holding History

StoneX Group’s Portfolio HKPD Stock Details HKPD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$52.4K	Buy	102,310 +62,915	+160%	+$34.4K	﹤0.01%	1222
2026 Q1	$22.4K	Sell	39,395 -3,889	-9%	-$2.83K	﹤0.01%	827
2025 Q4	$35.7K	Buy	+43,284	New	+$46.4K	﹤0.01%	947

Other funds holding HKPD

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

StoneX Group's HKPD Position: Q2 2026 in Review

StoneX Group increased its Cellyan Biotechnology (HKPD) stake by 160% in Q2 2026, buying an estimated $34.4K and bringing the position to 102,310 shares worth $52.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1222.

StoneX Group first reported a position in HKPD in Q4 2025 and has held it in 3 quarters since. 6 funds tracked by Wall St. Rank hold HKPD as of Q2 2026.

StoneX Group held 102,310 shares of Cellyan Biotechnology worth $52.4K as of Q2 2026.
StoneX Group bought 62,915 Cellyan Biotechnology shares in Q2 2026, an estimated $34.4K.
Cellyan Biotechnology made up ﹤0.01% of StoneX Group's portfolio in Q2 2026, its #1222 holding.
StoneX Group first reported a position in Cellyan Biotechnology in Q4 2025 and has held it in 3 quarters since.
6 funds tracked by Wall St. Rank held Cellyan Biotechnology as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.